Ascites in acute pancreatitis: A window into disease severity

Acute pancreatitis (AP) is a complex and potentially life-threatening inflammatory condition with a highly variable clinical course, ranging from mild, self-limiting episodes to severe necrotizing forms. Among its common complications ascites has traditionally been viewed as a passive byproduct of peritoneal inflammation and enzymatic leakage with limited diagnostic or prognostic utility. However, growing evidence challenges this perspective, suggesting that ascitic fluid in AP represents a dynamic and clinically meaningful component of disease progression. In this editorial we reflected on the findings presented by Rao et al, who highlighted the diagnostic, prognostic, and therapeutic significance of ascitic fluid in AP. Easily accessible markers such as lactate dehydrogenase may provide early prognostic insight while emerging molecular biomarkers and cytokine profiles offer promise for more precise risk stratification and individualized therapy. We argue that the systematic evaluation of ascitic fluid should be integrated into the clinical management of moderate to severe AP. Incorporating ascites analysis into standard diagnostic protocols may enhance early risk assessment, inform therapeutic decisions, and ultimately improve patient outcomes. Ascitic fluid should be recognized as a clinically valuable marker and an important source of information in the evolving landscape of AP care.